CNP 107
Alternative Names: CNP-107Latest Information Update: 19 Sep 2022
At a glance
- Originator Cour Pharmaceutical Development
- Class Skin disorder therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Vitiligo
Most Recent Events
- 13 Sep 2022 Preclinical trials in Vitiligo in USA (unspecified route) (Cour Pharmaceutical Development pipeline; September 2022)